Preliminary results of a phase I, first-in-human, dose escalation study of IMM2902 in patients with HER2-expressing advanced solid tumors

被引：0
|
作者：
Meng, Yanchun
Zhang, Jian
Zhao, Chuanhua
Cheng, Ying
Zhu, Liming
Song, Zhengbo
Xu, Nong
Wang, Zhen
Wang, Yanping
Du, Yiqun
Jing, Deqiang
Chen, Dinglu
Qu, Qiaofeng
Zhao, Xiwen
Li, Wei
Lu, Qiying
Tian, Wenzhi
Xu, Jianming
机构：
[1] Fudan Univ, Shanghai Canc Ctr, Phase Clin Trial Ctr 1, Shanghai, Peoples R China
[2] Chinese Peoples Liberat Army Gen Hosp, Beijing, Peoples R China
[3] Sch Med, Beijing, Peoples R China
[4] Jilin Canc Hosp, Changchun, Peoples R China
[5] Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Hangzhou, Peoples R China
[6] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Hangzhou, Peoples R China
[7] Linyi Canc Hosp, Linyi, Shandong, Peoples R China
[8] ImmuneOnco Biopharmaceut Shanghai Inc, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15185
引用
收藏
页数：1
相关论文
共 50 条
  • [21] First-in-Human, Dose Escalation and Expansion Study of MT-6402 in Patients With PD-L1 Expressing Advanced Solid Tumors
    Spigel, D. R.
    Anand, B.
    Carroll, K.
    Dekker, J.
    Georgy, A.
    Hankins, S.
    Rethy, A.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1102 - S1102
  • [22] A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors
    Jeffrey R. Infante
    David S. Mendelson
    Howard A. Burris
    Johanna C. Bendell
    Anthony W. Tolcher
    Michael S. Gordon
    Heidi H. Gillenwater
    Shirin Arastu-Kapur
    Hansen L. Wong
    Kyriakos P. Papadopoulos
    Investigational New Drugs, 2016, 34 : 216 - 224
  • [23] A first-in-human (FIH) phase I study of SAR12544, a novel selective MET kinase inhibitor, in patients (pts) with advanced solid tumors: Dose escalation results
    Angevin, Eric
    Spitaleri, Gianluca
    Hollebecque, Antoine
    De Pas, Tommaso
    Soria, Jean-Charles
    Harnols, Marzia
    Mazuir, Florent
    Assadourlan, Sylvie
    De Marinis, Filippo
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [24] Phase I trial of fruquintinib in patients with advanced solid tumors; Results of the dose escalation phase
    Wang-Gillam, A.
    Yeckes-Rodin, H.
    Kosmo, M. A.
    Stanton, T.
    Park, H.
    Songhua, F.
    Sauter, N. P.
    Kania, M.
    ANNALS OF ONCOLOGY, 2019, 30 : 175 - +
  • [25] Results of a first-in-human, dose-escalation phase 1 study of the ERK1/2 inhibitor ATG-017 in patients with advanced solid tumors
    Wahlroos, Sara
    Teng, Christina
    Tran, Ben
    Voskoboynik, Mark
    Gan, Hui Kong
    Spencer, Andrew
    Kudva, Anupa
    Song, Ming
    Lynch, Kevin
    Yu, Zhinuan
    Desai, Jayesh
    Lemech, Charlotte Rose
    Lifehouse, Chris O'Brien
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [26] Results from the first-in-human study of ATR inhibitor, IMP9064 monotherapy dose escalation in patients with advanced solid tumors
    Lin, C-C.
    Schneider, R.
    Gutierrez, M.
    Shen, L.
    Chung, K.
    Doroshow, D. B.
    Gao, B.
    Millward, M.
    Hsieh, C-Y.
    Xu, C.
    Cai, S. X.
    Tian, Y. E.
    Liu, L.
    Shen, C.
    Tan, Y.
    He, Y.
    Zhang, C.
    Li, L.
    Ma, M.
    Xu, L.
    ANNALS OF ONCOLOGY, 2024, 35 : S503 - S504
  • [27] A phase I, first-in-human, dose-escalation and dose expansion study of the multitarget kinase inhibitor TT-00420 in patients with advanced solid tumors.
    Piha-Paul, Sarina Anne
    Wan, Qunfang
    Xiong, Wendy
    Peng, Peng
    Yang, Xiaoju
    Wu, Henry
    Ngo, Brenda
    Wu, Frank
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [28] Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors
    Mathiot, Laurent
    Combarel, David
    Cagnat, Justin
    Delahousse, Julia
    Ouali, Kaissa
    Marabelle, Aurelien
    Loriot, Yohann
    Ponce, Santiago
    Champiat, Stephane
    Broutin, Sophie
    Danlos, Francois-Xavier
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (05)
  • [29] Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors
    Joerger, Markus
    Calvo, Emiliano
    Laubli, Heinz
    Lopez, Juanita
    Alonso, Guzman
    de la Fuente, Elena Corral
    Hess, Dagmar
    Konig, David
    Perez, Vicky Sanchez
    Bucher, Christoph
    Jethwa, Sangeeta
    Garralda, Elena
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (11)
  • [30] A first-in-human phase 1 dose escalation study of FF-10850 (liposomal topotecan) in patients with advanced solid tumors.
    Matulonis, Ursula A.
    Janku, Filip
    Moser, Justin C.
    Fu, Siqing
    Wages, David S.
    Wheeler, Catherine A.
    Mori, Mikinaga
    Shimoyama, Susumu
    Yamada, Naoki
    Subach, Ruth Ann
    Cheung, Kin
    Madden, Timothy
    Maier, Gary
    Johansen, Mary
    Falchook, Gerald Steven
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345